Transcriptional Changes Induced by the Tumor Dormancy-associated MicroRNA-190

Overview

Journal Transcription

Specialty Molecular Biology

Date 2013 Jul 19

PMID 23863200

Citations 32

Authors

Nava Almog

Christine Briggs

Afshin Beheshti

Lili Ma

Kathleen P Wilkie

Edward Rietman

Lynn Hlatky

Affiliations

Soon will be listed here.

Abstract

Tumor dormancy is a highly prevalent stage in cancer progression. We have previously generated and characterized in vivo experimental models of human tumor dormancy in which micro-tumors remain occult until they spontaneously shift into rapid tumor growth. We showed that the dormant micro-tumors undergo a stable microRNA (miRNA) switch during their transition from dormancy to a fast-growing phenotype and reported the identification of a consensus signature of human tumor dormancy-associated miRNAs (DmiRs). miRNA-190 (miR-190) is among the most upregulated DmiRs in all dormant tumors analyzed. Upregulation of miR-190 led to prolonged tumor dormancy in otherwise fast-growing glioblastomas and osteosarcomas. Here we investigate the transcriptional changes induced by miR-190 expression in cancer cells and show similar patterns of miR-190 mediated transcriptional reprogramming in both glioblastoma and osteosarcoma cells. The data suggests that miR-190 mediated effects rely on an extensive network of molecular changes in tumor cells and that miR-190 affects several transcriptional factors, tumor suppressor genes and interferon response pathways. The molecular mechanisms governing tumor dormancy described in this work may provide promising targets for early prevention of cancer and may lead to novel treatments to convert the malignant tumor phenotype into an asymptomatic dormant state.

Citing Articles

Towards understanding cancer dormancy over strategic hitching up mechanisms to technologies.

Yang S, Seo J, Choi J, Kim S, Kuk Y, Park K Mol Cancer. 2025; 24(1):47.

PMID: 39953555 PMC: 11829473. DOI: 10.1186/s12943-025-02250-9.

Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence.

Tufail M, Jiang C, Li N Mil Med Res. 2025; 12(1):7.

PMID: 39934876 PMC: 11812268. DOI: 10.1186/s40779-025-00595-2.

miR 204-5p inhibits apoptosis in dacarbazine-treated melanoma cells.

Palkina N, Sergeeva E, Ruksha T Oncol Res. 2023; 29(6):393-400.

PMID: 37304648 PMC: 10208032. DOI: 10.32604/or.2022.025816.

Cellular Dormancy in Cancer: Mechanisms and Potential Targeting Strategies.

Min H, Lee H Cancer Res Treat. 2023; 55(3):720-736.

PMID: 36960624 PMC: 10372609. DOI: 10.4143/crt.2023.468.

Quiescent Cancer Cells-A Potential Therapeutic Target to Overcome Tumor Resistance and Relapse.

Lindell E, Zhong L, Zhang X Int J Mol Sci. 2023; 24(4).

PMID: 36835173 PMC: 9959385. DOI: 10.3390/ijms24043762.

References

Zhang Y, Li M, Wang H, Fisher W, Lin P, Yao Q . Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg. 2008; 33(4):698-709. PMC: 2933040. DOI: 10.1007/s00268-008-9833-0. View

Zhang B, Pan X, Cobb G, Anderson T . microRNAs as oncogenes and tumor suppressors. Dev Biol. 2006; 302(1):1-12. DOI: 10.1016/j.ydbio.2006.08.028. View

Ventura A, Jacks T . MicroRNAs and cancer: short RNAs go a long way. Cell. 2009; 136(4):586-91. PMC: 3910108. DOI: 10.1016/j.cell.2009.02.005. View

Almog N, Ma L, Schwager C, Brinkmann B, Beheshti A, Vajkoczy P . Consensus micro RNAs governing the switch of dormant tumors to the fast-growing angiogenic phenotype. PLoS One. 2012; 7(8):e44001. PMC: 3432069. DOI: 10.1371/journal.pone.0044001. View

Guo H, Ingolia N, Weissman J, Bartel D . Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010; 466(7308):835-40. PMC: 2990499. DOI: 10.1038/nature09267. View

Udagawa T . Tumor dormancy of primary and secondary cancers. APMIS. 2008; 116(7-8):615-28. DOI: 10.1111/j.1600-0463.2008.01077.x. View

Almog N, Ma L, Raychowdhury R, Schwager C, Erber R, Short S . Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res. 2009; 69(3):836-44. DOI: 10.1158/0008-5472.CAN-08-2590. View

Stenman G, Andersson M, Andren Y . New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer. Cell Cycle. 2010; 9(15):2986-95. PMC: 3040924. DOI: 10.4161/cc.9.15.12515. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

10.

Almog N, Henke V, Flores L, Hlatky L, Kung A, Wright R . Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J. 2006; 20(7):947-9. DOI: 10.1096/fj.05-3946fje. View

11.

Lowery A, Miller N, Devaney A, McNeill R, Davoren P, Lemetre C . MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 2009; 11(3):R27. PMC: 2716495. DOI: 10.1186/bcr2257. View

12.

Bray I, Bryan K, Prenter S, Buckley P, Foley N, Murphy D . Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One. 2009; 4(11):e7850. PMC: 2773120. DOI: 10.1371/journal.pone.0007850. View

13.

De Preter K, Mestdagh P, Vermeulen J, Zeka F, Naranjo A, Bray I . miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. Clin Cancer Res. 2011; 17(24):7684-92. PMC: 4008338. DOI: 10.1158/1078-0432.CCR-11-0610. View

14.

Schoggins J, Rice C . Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol. 2012; 1(6):519-25. PMC: 3274382. DOI: 10.1016/j.coviro.2011.10.008. View

15.

OReilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W . Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88(2):277-85. DOI: 10.1016/s0092-8674(00)81848-6. View

16.

Aguirre-Ghiso J . Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007; 7(11):834-46. PMC: 2519109. DOI: 10.1038/nrc2256. View

17.

Beezhold K, Liu J, Kan H, Meighan T, Castranova V, Shi X . miR-190-mediated downregulation of PHLPP contributes to arsenic-induced Akt activation and carcinogenesis. Toxicol Sci. 2011; 123(2):411-20. PMC: 3179680. DOI: 10.1093/toxsci/kfr188. View

18.

Carthew R, Sontheimer E . Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009; 136(4):642-55. PMC: 2675692. DOI: 10.1016/j.cell.2009.01.035. View

19.

Brackstone M, Townson J, Chambers A . Tumour dormancy in breast cancer: an update. Breast Cancer Res. 2007; 9(3):208. PMC: 1929094. DOI: 10.1186/bcr1677. View

20.

Guglielmelli P, Tozzi L, Pancrazzi A, Bogani C, Antonioli E, Ponziani V . MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Exp Hematol. 2007; 35(11):1708-18. DOI: 10.1016/j.exphem.2007.08.020. View